hucMSC-sEV for Reversing Beta Cell Dedifferentiation in T2DM
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 Diabetes Mellitus (T2DM) primarily focus on alleviating symptoms by enhancing insulin sensitivity and secretion, but they do not effectively address the maintenance of endogenous β cell mass or reverse β cell dedifferentiation and apoptosis, leading to chronic complications.
Innovation Solution
The use of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEV) is proposed as a drug to improve pancreatic islet function, specifically by culturing hucMSCs, obtaining the sEV through differential centrifugation, and administering them to increase β cell mass and reverse apoptosis and dedifferentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional hypoglycemic drugs are used to enhance insulin sensitivity and secretion, then blood glucose levels are reduced, but endogenous β cell mass is not maintained and β cell dedifferentiation and apoptosis are not reversed
Solution Approach 1:
The patent uses small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells as an intermediary carrier to deliver therapeutic cargo to pancreatic β cells. These sEVs mediate the transfer of beneficial molecules that protect β cells from dedifferentiation and apoptosis, thereby maintaining endogenous β cell mass without relying solely on conventional drugs that only manage blood glucose levels.
Solution Approach 2:
The patent changes the therapeutic approach from managing blood glucose levels (conventional drug therapy) to directly protecting and regenerating β cells through sEV treatment. This parameter shift from metabolic control to cellular regeneration addresses the root cause of T2DM by preserving β cell mass and function, thereby improving long-term disease management and reducing complications.
2Object-affected harmful factors
If conventional treatments focus on symptom alleviation through insulin sensitivity enhancement, then blood glucose is controlled, but the underlying β cell damage progresses leading to chronic complications
Solution Approach 1:
The patent applies preliminary protective action by administering sEVs before significant β cell loss occurs. The sEVs contain protective molecules that preemptively shield β cells from stress-induced dedifferentiation and apoptosis, preventing the progression to chronic complications rather than merely responding to established damage.
Solution Approach 2:
The patent converts the harmful effects of chronic hyperglycemia and inflammation into beneficial outcomes by using sEVs that deliver protective cargo to β cells. The sEVs transform the pathological environment into a protective one, enabling β cells to withstand stress and maintain their differentiated state despite the presence of diabetic conditions.
3Quantity of substance
If β cell compensation through increased insulin production is allowed to continue long-term, then initial glucose control is maintained, but β cell stress leads to dedifferentiation and apoptosis
Solution Approach 1:
The patent provides beforehand cushioning to β cells by delivering protective molecules through sEVs before stress-induced damage occurs. This cushioning effect protects β cells from the damaging consequences of chronic insulin production demands, extending their functional lifespan while maintaining adequate insulin output for glucose control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hucMSC-sEV effectively reduces blood glucose levels, improves glucose tolerance, increases pancreatic islet volume, and reverses β cell dedifferentiation and apoptosis, providing a novel strategy for treating T2DM with reduced side effects and increased β cell mass.
Implementation Method 1
The present disclosure provides a preparation method of the hucMSC-SEV, including: culturing a human umbilical cord mesenchymal stem cell (hucMSC) to a cell fusion of 70% to 80%, transferring the hucMSC into a minimum essential medium (MEM)-α medium to allow culturing for 40 h to 50 h, and collecting a resulting medium supernatant to allow differential centrifugation to obtain a precipitate, namely the hucMSC-SEV
Data Source
AI summary
The present disclosure provides use of a human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (hucMSC-sEV) in preparation of a drug for treating type 2 diabetes mellitus (T2DM), and belongs to the technical field of biomedicine. In the present disclosure, experiments have verified that the hucMSC-SEV can effectively reduce blood glucose in a db/db mouse model, improve a morphological disorder of pancreatic islets, and increase a number of β cells. Moreover, the hucMSC-sEV can also remodel pancreatic β cells by reversing apoptosis and dedifferentiation of the β cells. It is confirmed that the hucMSC-sEV is an effective pharmaceutical ingredient that improves pancreatic islet functions, and can effectively ameliorate T2DM, regulate glucose homeostasis, improve a pancreatic islet structure, and increase a quality of the pancreatic islet β cells, thereby achieving therapeutic effects from a root cause of the disease.